Key clinical point: Serial ketamine infusions eliminated suicidal ideation in more than two-thirds of patients but at significantly higher doses than those recently approved for Janssen’s new nasal esketamine spray (Spravato).
Major finding: Among 144 patients, IV ketamine diminished suicidal ideation in 118 (82%) and eliminated them in 98 (68%).
Study details: Single-center review of 235 patients with treatment-resistant depression.
Disclosures: The report had no external funding, and Dr. Calabrese had no disclosures.
REPORTING FROM APA 2019